Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Voyager Therapeutics and MiNK Therapeutics' top-line revenue, earnings per share and valuation.
Get Voyager Therapeutics alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $37.42 million | 6.45 | -$71.20 million | ($0.46) | -13.59 |
| MiNK Therapeutics | $690,000.00 | 112.62 | -$30.21 million | ($0.78) | -2.95 |
MiNK Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
59.4% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 1.1% of MiNK Therapeutics shares are held by institutional investors. 22.0% of Voyager Therapeutics shares are held by insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.Volatility & Risk
Voyager Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500.
Profitability
This table compares Voyager Therapeutics and MiNK Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -24.21% | -21.97% | -8.65% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
Analyst Recommendations
This is a breakdown of recent recommendations for Voyager Therapeutics and MiNK Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Voyager Therapeutics currently has a consensus target price of $6.00, indicating a potential downside of 4.00%. MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 204.35%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Voyager Therapeutics.
Summary
Voyager Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.
About Voyager Therapeutics
(Get Rating)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.